But! Nice refuses to use J & J imbruvica for NHL

Source: Biovalley 2016-10-25 although imbruvica (ibrutinib), a blockbuster anticancer drug jointly developed by Albright and Johnson & Johnson, is a green light in US and European regulation (6 indications have been approved in the US and 5 indications have been approved in Europe), like many star drugs, nice, the UK medical cost control agency Once again, Johnson was shut This time nice refused to approve the treatment of non Hodgkin's lymphoma by imbruvica (ibrutinib) In the draft guide, nice said that imbruvica (ibrutinib) was too expensive and cost-effective to include the drug in healthcare Imbruvica has been approved in Europe for the treatment of Waldenstrom's macroglobulinaemia, a rare, slow-moving non Hodgkin's lymphoma Imbruvica can be used not only in patients who have received previous treatment, but also as a first-line treatment alternative to chemotherapy According to a statement issued by nice, although nice can understand the strong demand of these patients for the drug, the current quotation and data provided by Johnson & Johnson show that the cost performance of the drug is not high, far beyond the range that NHS can bear However, this is not the first time that nice has rejected imbruvica Previously, nice refused to include the drug in the guidelines The indication was chronic lymphocytic leukemia (CLL), because the current clinical data "cannot prove the accuracy of its efficacy" and "the price is too expensive" Ironically, shortly after nice released this guideline, imbruvica was approved by FDA and EMA as the first-line treatment plan for CLL, and now the drug has been approved in 48 countries around the world Johnson & Johnson said that the current nice evaluation system can not meet the needs of cancer patients, which is not good news for cancer patients in the UK Imbruvica (ibrutinib) is the first oral Burton tyrosine kinase (Btk) inhibitor, which plays an anti-cancer role by inhibiting the BTK required by tumor cell replication and metastasis Imbruvica can block the signal pathway of uncontrolled proliferation and diffusion of malignant B cells, help to kill and reduce the number of cancer cells, and delay the progression of cancer In clinical trials, the single drug and combination therapy of imbruvica has shown a strong effect on a wide range of hematological malignancies, including chronic lymphoblastic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom megaglobulinemia (WM), diffuse large B-cell lymphocarcinoma (clbcl), follicular lymphoma (FL), multiple myeloma（ Mm) and marginal zone lymphoma (MZL).